Literature DB >> 23973305

Sex-independent suppression of experimental inflammatory pain by minocycline in two mouse strains.

Leandro F S Bastos1, Júlia D M Prazeres, Adriana M Godin, Raquel R Menezes, Darly G Soares, Wallace C Ferreira, Marcela M G B Dutra, Renes R Machado, Márcio M Coelho.   

Abstract

The research on sex differences in nociception and antinociception as well as sex and gender differences in pain and analgesia is a maturing field. There is a vast literature showing experimental and clinical pain suppressive effects induced by minocycline, especially in inflammatory pain. However, as far as we know, possible qualitative or quantitative sex differences in those effects remained to be examined. By employing the formalin test, which has two phases of experimental pain behavior that models nociceptive pain (i.e., first phase) and inflammatory pain (i.e., second phase), we initially evaluated the effect induced by minocycline in female or male C57BL/6 mice. The treatment reduced the second phase of licking behavior in both females and males, and the effects were quantitatively similar in both sexes. Likewise, the same sex-independent effect was observed in Swiss mice, suggesting a genotype-unspecific sex-independent effect. While minocycline is already being tested in clinical trials, this appears to be the first preclinical investigation of sex differences in the experimental pain suppressive effects induced by this widely studied drug. The independence of sex in the antinociceptive effect induced by minocycline may be hopefully translated to gender-independent analgesic effects, which would be surely promising in a therapeutic paradigm.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Formalin test; Gender; Mice; Nociception; Sex; Tetracyclines

Mesh:

Substances:

Year:  2013        PMID: 23973305     DOI: 10.1016/j.neulet.2013.08.026

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

Review 1.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 2.  Qualitative sex differences in pain processing: emerging evidence of a biased literature.

Authors:  Jeffrey S Mogil
Journal:  Nat Rev Neurosci       Date:  2020-05-21       Impact factor: 34.870

3.  Sex-Dependent Glial Signaling in Pathological Pain: Distinct Roles of Spinal Microglia and Astrocytes.

Authors:  Gang Chen; Xin Luo; M Yawar Qadri; Temugin Berta; Ru-Rong Ji
Journal:  Neurosci Bull       Date:  2017-06-05       Impact factor: 5.203

4.  Minocycline Protects PC12 Cells Against Cadmium-Induced Neurotoxicity by Modulating Apoptosis.

Authors:  Mersedeh Shayan; Soghra Mehri; Bibi Marjan Razavi; Hossein Hosseinzadeh
Journal:  Biol Trace Elem Res       Date:  2022-06-06       Impact factor: 3.738

5.  Binge Ethanol Consumption Increases Inflammatory Pain Responses and Mechanical and Cold Sensitivity: Tigecycline Treatment Efficacy Shows Sex Differences.

Authors:  Susan E Bergeson; Henry Blanton; Joseph M Martinez; David C Curtis; Caitlyn Sherfey; Brandon Seegmiller; Patrick C Marquardt; Jessica A Groot; Clayton L Allison; Christian Bezboruah; Josée Guindon
Journal:  Alcohol Clin Exp Res       Date:  2016-11-14       Impact factor: 3.455

6.  Ulinastatin Exhibits Antinociception in Rat Models of Acute Somatic and Visceral Pain Through Inhibiting the Local and Central Inflammation.

Authors:  Mei-Xiang Zhan; Li Tang; Yun-Fei Lu; Huang-Hui Wu; Yi-Qing Zou; Zhi-Bin Guo; Zhong-Mou Shi; Chen-Long Yang; Fei Yang; Guo-Zhong Chen
Journal:  J Pain Res       Date:  2021-05-04       Impact factor: 3.133

Review 7.  Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?

Authors:  Kufreobong E Inyang; Joseph K Folger; Geoffroy Laumet
Journal:  J Neuroimmune Pharmacol       Date:  2021-05-26       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.